Crucell lays off 60 Berna people
London – The Dutch vaccine developer Crucell NV will be concentrating its research and development activities at its headquarters in Leiden. The restructuring will result in the laying-off of 60 Berna staff in Bern. At the end of last year, the Belgian biotech company overtook its Swiss rivals Berna Biotech in an all-stock deal. The decision came after clinical studies for the company’s lead product, a vaccine candidate for the prevention of an Pseudomonas aeruginosa infection, were suspended. During the meger talks, Crucell had calmed opposing Berna stockholders with the promise that it would maintain the staff in Bern. With the new growth potential that the two companies now possess, an extension in the number of staff in Bern would be possible, said Crucell, before the merger was completed.